Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action on behalf of purchasers of securities of Novo Nordisk A/S between November 2, 2022 and December 19, 2024, ...

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

Enveric Biosciences’ (NASDAQ:ENVB) wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements ...